GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Price-to-Free-Cash-Flow

Nymox Pharmaceutical (Nymox Pharmaceutical) Price-to-Free-Cash-Flow : N/A (As of Apr. 25, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Price-to-Free-Cash-Flow?

As of today (2024-04-25), Nymox Pharmaceutical's share price is $0.32. Nymox Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.05. Hence, Nymox Pharmaceutical's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Nymox Pharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Nymox Pharmaceutical's highest Price-to-Free-Cash-Flow Ratio was 86.02. The lowest was 0.00. And the median was 80.56.

NYMXF's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.19
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Nymox Pharmaceutical's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.70% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 8.10% per year.

During the past 13 years, Nymox Pharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 26.30% per year. The lowest was -38.10% per year. And the median was 0.30% per year.


Nymox Pharmaceutical Price-to-Free-Cash-Flow Historical Data

The historical data trend for Nymox Pharmaceutical's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Price-to-Free-Cash-Flow Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nymox Pharmaceutical's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Nymox Pharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Price-to-Free-Cash-Flow falls into.



Nymox Pharmaceutical Price-to-Free-Cash-Flow Calculation

Nymox Pharmaceutical's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.32/-0.049
=N/A

Nymox Pharmaceutical's Share Price of today is $0.32.
Nymox Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Nymox Pharmaceutical  (OTCPK:NYMXF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Nymox Pharmaceutical Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GlobeNewswire GlobeNewswire 11-15-2021

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023